Should I buy or sell Verastem stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Verastem in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" VSTM shares. View VSTM analyst ratings or view top-rated stocks .

What is Verastem's stock price target for 2024?

7 analysts have issued 1-year price objectives for Verastem's shares. Their VSTM share price targets range from $17.50 to $36.00. On average, they predict the company's share price to reach $28.79 in the next year. This suggests a possible upside of 192.5% from the stock's current price. View analysts price targets for VSTM or view top-rated stocks among Wall Street analysts .

How have VSTM shares performed in 2024?

Verastem's stock was trading at $8.14 at the beginning of 2024. Since then, VSTM shares have increased by 20.9% and is now trading at $9.84. View the best growth stocks for 2024 here .

Are investors shorting Verastem?

Verastem saw a drop in short interest in the month of March. As of March 31st, there was short interest totaling 634,500 shares, a drop of 17.9% from the March 15th total of 773,100 shares. Based on an average trading volume of 148,900 shares, the short-interest ratio is currently 4.3 days. Currently, 3.1% of the company's shares are sold short. View Verastem's Short Interest .

When is Verastem's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our VSTM earnings forecast .

How were Verastem's earnings last quarter?

Verastem, Inc. (NASDAQ:VSTM) posted its quarterly earnings results on Thursday, March, 14th. The biopharmaceutical company reported ($1.02) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.82) by $0.20.

When did Verastem's stock split?

Verastem shares reverse split on Thursday, June 1st 2023. The 1-12 reverse split was announced on Thursday, June 1st 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 1st 2023. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

What is Robert Forrester's approval rating as Verastem's CEO?

11 employees have rated Verastem Chief Executive Officer Robert Forrester on Glassdoor.com . Robert Forrester has an approval rating of 100% among the company's employees. This puts Robert Forrester in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Verastem own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Verastem investors own include TherapeuticsMD (TXMD) , Micron Technology (MU) , Novavax (NVAX) , Inovio Pharmaceuticals (INO) , Gilead Sciences (gild) , Sorrento Therapeutics (SRNE) , SCYNEXIS (SCYX) , TG Therapeutics (TGTX) , Amarin (AMRN) and Viking Therapeutics (VKTX) .

Who are Verastem's major shareholders?

Verastem's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Cannon Global Investment Management LLC (0.04%). Insiders that own company stock include Brian M Stuglik , Dan Paterson , Daniel Calkins and Robert E Gagnon . View institutional ownership trends .

How do I buy shares of Verastem?

Shares of VSTM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:VSTM

Verastem (VSTM) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free VSTM Stock Alerts

$9.84

-0.39 (-3.81%)

(As of 04/19/2024 ET)

Compare

Today's Range: $9.56
▼
$10.36
50-Day Range: $9.84
▼
$13.12
52-Week Range: $4.26
▼
$15.18

Volume: 150,977 shs
Average Volume: 103,481 shs
Market Capitalization: $249.05 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $28.79

Get Verastem alerts:

Verastem MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 192.5% Upside
$28.79 Price Target
Short Interest: Healthy
3.10% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.23
Based on 3 Articles This Week
Insider Trading: Selling Shares
$6,619 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($4.31) to ($2.84) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.88 out of 5 stars

Medical Sector

386th out of 911 stocks

Pharmaceutical Preparations Industry

174th out of 419 stocks

3.5

Analyst's Opinion

Consensus Rating
Verastem has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Verastem has only been the subject of 2 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
3.10% of the float of Verastem has been sold short.
Short Interest Ratio / Days to Cover
Verastem has a short interest ratio ("days to cover") of 4.3.
Change versus previous month
Short interest in Verastem has recently decreased by 17.93%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Verastem does not currently pay a dividend.
Dividend Growth
Verastem does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for VSTM.

2.3

News and Social Media Coverage

News Sentiment
Verastem has a news sentiment score of 0.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.51 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Verastem this week, compared to 2 articles on an average week.
Search Interest
9 people have searched for VSTM on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.
MarketBeat Follows
Only 3 people have added Verastem to their MarketBeat watchlist in the last 30 days. This is a decrease of -57% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Verastem insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,619.00 in company stock.
Percentage Held by Insiders
Only 2.90% of the stock of Verastem is held by insiders.
Percentage Held by Institutions
88.37% of the stock of Verastem is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Verastem are expected to grow in the coming year, from ($4.31) to ($2.84) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Verastem is -2.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Verastem is -2.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Verastem has a P/B Ratio of 4.33. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Verastem Stock (NASDAQ:VSTM)

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.

VSTM Stock Price History

30 days | 90 days | 365 days | Advanced Chart

VSTM Stock News Headlines

April 19, 2024 | finance.yahoo.com

Verastem, Inc. (VSTM)

April 18, 2024 | marketwatch.com

Verastem Oncology Names John Hayslip as Chief Medical Officer

April 20, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

April 18, 2024 | businesswire.com

Verastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical Officer

April 13, 2024 | americanbankingnews.com

Verastem, Inc. (NASDAQ:VSTM) Short Interest Down 17.9% in March

April 12, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Shattuck Labs (STTK) and Verastem (VSTM)

April 12, 2024 | americanbankingnews.com

Verastem (NASDAQ:VSTM) Stock Price Crosses Above 200-Day Moving Average of $9.47

April 10, 2024 | investing.com

Verastem CFO sells shares to cover tax obligations

April 20, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

April 4, 2024 | businesswire.com

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 27, 2024 | markets.businessinsider.com

Verastem’s Strategic Advancements and Financial Stability Underscore Buy Rating

March 22, 2024 | investing.com

Verastem director sells over $8,500 in company stock

March 20, 2024 | finance.yahoo.com

VSTM Apr 2024 11.000 call

March 19, 2024 | markets.businessinsider.com

Verastem: Financial Resilience and Promising Drug Pipeline Despite Short-Term Losses

March 18, 2024 | businesswire.com

Global Patient Survey Results Reveal Significant Negative Impact on Social, Emotional and Mental Well-Being for People Living with Low-Grade Serous Ovarian Cancer

March 16, 2024 | finance.yahoo.com

VSTM Apr 2024 14.000 call

March 14, 2024 | benzinga.com

Recap: Verastem Q4 Earnings

March 14, 2024 | investorplace.com

VSTM Stock Earnings: Verastem Misses EPS for Q4 2023

March 14, 2024 | businesswire.com

Verastem Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates

March 11, 2024 | finance.yahoo.com

Verastem Oncology Announces Multiple Oral Presentations at SGO 2024 Annual Meeting on Women’s Cancer that Highlight Advances in Low-Grade Serous Ovarian Cancer Research and Reinforce Commitment to Addressing Urgent Unmet Needs

March 11, 2024 | businesswire.com

Verastem Oncology Announces Multiple Oral Presentations at SGO 2024 Annual Meeting on Women's Cancer that Highlight Advances in Low-Grade Serous Ovarian Cancer Research and Reinforce Commitment to Addressing Urgent Unmet Needs

March 10, 2024 | finance.yahoo.com

VSTM Mar 2024 2.000 put

March 6, 2024 | markets.businessinsider.com

Verastem Oncology Granted FDA Orphan Drug Designation For Avutometinib In Ovarian Cancer

March 6, 2024 | msn.com

Verastem gets FDA orphan drug status for low-grade ovarian cancer therapy

March 5, 2024 | businesswire.com

Verastem Oncology Receives Orphan Drug Designation from FDA for Avutometinib Alone or in Combination With Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

March 5, 2024 | businesswire.com

Verastem Oncology Announces Preclinical Presentations for New Oral G12D Inhibitor and for Avutometinib and Defactinib Combination as a Backbone of Therapy for RAS/MAPK Driven Cancers at AACR Annual Meeting 2024

February 23, 2024 | benzinga.com

Verastem Stock (NASDAQ:VSTM), Short Interest Report

See More Headlines

Receive VSTM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Verastem and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/14/2024
Today: 4/20/2024
Next Earnings (Estimated): 5/14/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: Biotechnology
Current Symbol: NASDAQ:VSTM
CUSIP: 92337C10
CIK: 1526119
Web: www.verastem.com
Phone: (781) 292-4200
Fax: N/A
Employees: 73
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $28.79
High Stock Price Target: $36.00
Low Stock Price Target: $17.50
Potential Upside/Downside: +192.5%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($4.1004)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-87,370,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -127.00%
Return on Assets: -54.73%

Debt

Debt-to-Equity Ratio: 0.70
Current Ratio: 5.45
Quick Ratio: 5.45

Sales & Book Value

Annual Sales: $2.60 million
Price / Sales: 95.79
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.27 per share
Price / Book: 4.33

Miscellaneous

Outstanding Shares: 25,310,000
Free Float: 24,574,000
Market Cap: $249.05 million
Optionable: Optionable
Beta: 0.48

The Best High-Yield Dividend Stocks for 2024

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

Mr. Daniel W. Paterson (Age 63)
President, CEO & Director
Comp: $697.98k
Mr. Daniel Calkins (Age 36)
CFO and Principal Accounting & Financial Officer
Comp: $1.42M
Mr. Richard H. Aldrich M.B.A. (Age 70)
Founder and Consultant
Comp: $38.39k
Dr. Robert A. Weinberg Ph.D.
Co-Founder & Chair of Scientific Advisory Board
Dr. Piyush B. Gupta Ph.D.
Co-Founder
Dr. Michelle Dipp M.D. (Age 48)
Ph.D., Co-Founder
Mr. Robert Pintar M.B.A.
Senior Vice President of Technical Operations
Dr. Jonathan Pachter Ph.D. (Age 66)
Chief Scientific Officer
Comp: $238.18k
Mr. Nate Sanburn
Senior Vice President of Corporate Development & External Engagement
Dr. Hagop Youssoufian M.D. (Age 67)
M.Sc., Ph.D., Head of Medical Strategy

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

VSTM Stock Analysis - Frequently Asked Questions

Should I buy or sell Verastem stock right now?: 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Verastem in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" VSTM shares.
View VSTM analyst ratings or view top-rated stocks.
What is Verastem's stock price target for 2024?: 7 analysts have issued 1-year price objectives for Verastem's shares. Their VSTM share price targets range from $17.50 to $36.00. On average, they predict the company's share price to reach $28.79 in the next year. This suggests a possible upside of 192.5% from the stock's current price.
View analysts price targets for VSTM or view top-rated stocks among Wall Street analysts.
How have VSTM shares performed in 2024?: Verastem's stock was trading at $8.14 at the beginning of 2024. Since then, VSTM shares have increased by 20.9% and is now trading at $9.84.
View the best growth stocks for 2024 here.
Are investors shorting Verastem?: Verastem saw a drop in short interest in the month of March. As of March 31st, there was short interest totaling 634,500 shares, a drop of 17.9% from the March 15th total of 773,100 shares. Based on an average trading volume of 148,900 shares, the short-interest ratio is currently 4.3 days. Currently, 3.1% of the company's shares are sold short.
View Verastem's Short Interest.
When is Verastem's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our VSTM earnings forecast.
How were Verastem's earnings last quarter?: Verastem, Inc. (NASDAQ:VSTM) posted its quarterly earnings results on Thursday, March, 14th. The biopharmaceutical company reported ($1.02) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.82) by $0.20.

When did Verastem's stock split?: Verastem shares reverse split on Thursday, June 1st 2023. The 1-12 reverse split was announced on Thursday, June 1st 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 1st 2023. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.
What is Robert Forrester's approval rating as Verastem's CEO?: 11 employees have rated Verastem Chief Executive Officer Robert Forrester on Glassdoor.com. Robert Forrester has an approval rating of 100% among the company's employees. This puts Robert Forrester in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Verastem own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Verastem investors own include TherapeuticsMD (TXMD), Micron Technology (MU), Novavax (NVAX), Inovio Pharmaceuticals (INO), Gilead Sciences (gild), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), TG Therapeutics (TGTX), Amarin (AMRN) and Viking Therapeutics (VKTX).
Who are Verastem's major shareholders?: Verastem's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Cannon Global Investment Management LLC (0.04%). Insiders that own company stock include Brian M Stuglik, Dan Paterson, Daniel Calkins and Robert E Gagnon.
View institutional ownership trends.
How do I buy shares of Verastem?: Shares of VSTM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:VSTM) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial